ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Gilead Sciences, Menarini Group and Haisco Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Gilead SciencesMenarini GroupHaisco Pharmaceutical Group
studies on the registry73881159
open to participants now321453
phase 3 studies under way32211
reach primary completion within a year19721
programswith a study of their own in two years32727

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGilead SciencesMenarini GroupHaisco Pharmaceutical Group
Phase 1

Gilead Sciences: 6 of its 32 programs at phase 1

  1. GS-0151phase 1
  2. GS-0415phase 1
  3. GS-1206phase 1
  4. GS-2426phase 1
  5. GS-5319phase 1

and 1 more — sign in to see them all

19%

Menarini Group: 4 of its 7 programs at phase 1

  1. Tamsulosinphase 1
  2. KIF18A Inhibitor MEN2501phase 1
  3. Torsemidephase 1
  4. Ibuprofenphase 1
57%

Haisco Pharmaceutical Group: 14 of its 27 programs at phase 1

  1. HSK41959phase 1
  2. HSK46256phase 1
  3. HSK46575phase 1
  4. HSK47977phase 1
  5. HSK55879phase 1

and 9 more — sign in to see them all

52%
Phase 2

Gilead Sciences: 6 of its 32 programs at phase 2

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2
  2. denikitugphase 2
  3. GS-1179phase 2
  4. GS-4321phase 2
  5. PTM Cilofexor Dose Aphase 2

and 1 more — sign in to see them all

19%

Menarini Group: 2 of its 7 programs at phase 2

  1. KAT6 Inhibitor MEN2312phase 2
  2. RPX7009phase 2
29%

Haisco Pharmaceutical Group: 5 of its 27 programs at phase 2

  1. HSK42360phase 2
  2. HSK47388phase 2
  3. HSK55718phase 2
  4. Cetuximabphase 2
  5. HSK50042phase 2
19%
Phase 3

Gilead Sciences: 15 of its 32 programs at phase 3

  1. anitocabtagene autoleucelphase 3
  2. domvanalimabphase 3
  3. seladelparphase 3
  4. axicabtagene ciloleucelphase 3
  5. GS-3242phase 3

and 10 more — sign in to see them all

47%

Menarini Group: 1 of its 7 programs at phase 3

  1. elacestrantphase 3
14%

Haisco Pharmaceutical Group: 7 of its 27 programs at phase 3

  1. florensocatibphase 3
  2. HSK44459phase 3
  3. HSK39004phase 3
  4. HSK39297phase 3
  5. anrikefonphase 3

and 2 more — sign in to see them all

26%
Approved, new studies

Gilead Sciences: 5 of its 32 programs at approved, new studies

  1. sacituzumab govitecanapproved, new study
  2. lenacapavirapproved, new study
  3. tenofovir alafenamideapproved, new study
  4. bictegravirapproved, new study
  5. Emtricitabineapproved, new study
16%
00%

Haisco Pharmaceutical Group: 1 of its 27 programs at approved, new studies

  1. ciprofolapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Gilead Sciences10 readouts · 2 phase 3·

Gilead Sciences, Dec ’26: 2 programs whose next study reaches primary completion

  1. anitocabtagene autoleucelphase 3 · Dec 0 · NCT05396885
  2. sacituzumab govitecanapproved, new study · Dec 0 · NCT04617522
··

Gilead Sciences, Mar ’27: 4 programs whose next study reaches primary completion

  1. domvanalimabphase 3 · Mar 0 · NCT06727565
  2. GS-0151phase 1 · Mar 0 · NCT06902519
  3. lenacapavirapproved, new study · Mar 0 · NCT06749054
  4. Optimized Background Regimen (OBR)phase 3 · Mar 0 · NCT06749054
··

Gilead Sciences, Jun ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Emtricitabineapproved, new study · Jun 0 · NCT06337032
  2. tenofovir alafenamideapproved, new study · Jun 0 · NCT06337032
·

Gilead Sciences, Aug ’27: 2 programs whose next study reaches primary completion

  1. bictegravirapproved, new study · Aug 0 · NCT07645287
  2. GS-3242phase 3 · Aug 0 · NCT07645287
··
Menarini Group3 readouts · 0 phase 3

Menarini Group, Nov ’26: 1 program whose next study reaches primary completion

  1. elacestrantphase 3 · Nov 0 · NCT05596409
··········

Menarini Group, Oct ’27: 2 programs whose next study reaches primary completion

  1. RPX7009phase 2 · Oct 0 · NCT06828848
  2. KAT6 Inhibitor MEN2312phase 2 · Oct 24 · NCT06638307
Haisco Pharmaceutical Group9 readouts · 1 phase 3

Haisco Pharmaceutical Group, Nov ’26: 2 programs whose next study reaches primary completion

  1. florensocatibphase 3 · Nov 0 · NCT07915024
  2. HSK55718phase 2 · Nov 0 · NCT07551739

Haisco Pharmaceutical Group, Dec ’26: 3 programs whose next study reaches primary completion

  1. HSK46575phase 1 · Dec 0 · NCT07007910
  2. HSK39297phase 3 · Dec 5 · NCT07616700
  3. HSK47388phase 2 · Dec 20 · NCT07158268
··

Haisco Pharmaceutical Group, Mar ’27: 1 program whose next study reaches primary completion

  1. HSK44459phase 3 · Mar 0 · NCT07623486
··

Haisco Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HSK39004phase 3 · Jun 11 · NCT07658339
  2. cofrogliptinno phase · Jun 30 · NCT07122102
··

Haisco Pharmaceutical Group, Sep ’27: 1 program whose next study reaches primary completion

  1. HSK60002 tabletsphase 1 · Sep 0 · NCT07920809
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Gilead Sciences

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 6

Menarini Group

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 1

Haisco Pharmaceutical Group

New programs 1

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.

ConditionGilead SciencesMenarini GroupHaisco Pharmaceutical Group
Breast Neoplasms2 of 3 · compare here

Gilead Sciences in Breast Neoplasms: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. trifluridine tipiracil drug combinationphase 2
  4. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Breast Neoplasms in search

Menarini Group in Breast Neoplasms: 2 programs

  1. elacestrantphase 3
  2. KAT6 Inhibitor MEN2312phase 2

Their studies: Menarini Group’s studies of Breast Neoplasms in search

–
Diabetes Mellitus, Type 22 of 3 · compare here–

Menarini Group in Diabetes Mellitus, Type 2: 1 program

  1. Torsemidephase 1

Their studies: Menarini Group’s studies of Diabetes Mellitus, Type 2 in search

Haisco Pharmaceutical Group in Diabetes Mellitus, Type 2: 4 programs

  1. HSK7653phase 3
  2. Carbon-14phase 1
  3. Ranolazinephase 1
  4. cofrogliptinno phase

Their studies: Haisco Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Gilead Sciences in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. domvanalimabphase 3
  2. Topotecanphase 3
  3. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Carcinoma, Non-Small-Cell Lung in search

–

Haisco Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasms2 of 3 · compare here

Gilead Sciences in Colorectal Neoplasms: 2 programs

  1. denikitugphase 2
  2. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Colorectal Neoplasms in search

–

Haisco Pharmaceutical Group in Colorectal Neoplasms: 2 programs

  1. HSK42360phase 2
  2. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Neoplasms2 of 3 · compare here

Gilead Sciences in Neoplasms: 2 programs

  1. lurbinectedinphase 3
  2. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Neoplasms in search

–

Haisco Pharmaceutical Group in Neoplasms: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Neoplasms in search

Non-alcoholic Fatty Liver Disease2 of 3 · compare here

Gilead Sciences in Non-alcoholic Fatty Liver Disease: 2 programs

  1. seladelparphase 3
  2. cilofexorphase 3

Their studies: Gilead Sciences’ studies of Non-alcoholic Fatty Liver Disease in search

–

Haisco Pharmaceutical Group in Non-alcoholic Fatty Liver Disease: 1 program

  1. HSK31679phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Non-alcoholic Fatty Liver Disease in search

Renal Insufficiency2 of 3 · compare here–

Menarini Group in Renal Insufficiency: 1 program

  1. RPX7009phase 2

Their studies: Menarini Group’s studies of Renal Insufficiency in search

Haisco Pharmaceutical Group in Renal Insufficiency: 2 programs

  1. anrikefonphase 3
  2. HSK7653phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Renal Insufficiency in search

Lupus Nephritis2 of 3 · compare here

Gilead Sciences in Lupus Nephritis: 1 program

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2

Their studies: Gilead Sciences’ studies of Lupus Nephritis in search

–

Haisco Pharmaceutical Group in Lupus Nephritis: 1 program

  1. HSK39297phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Lupus Nephritis in search

Ovarian Neoplasms2 of 3 · compare here

Gilead Sciences in Ovarian Neoplasms: 1 program

  1. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Ovarian Neoplasms in search

Menarini Group in Ovarian Neoplasms: 1 program

  1. KIF18A Inhibitor MEN2501phase 1

Their studies: Menarini Group’s studies of Ovarian Neoplasms in search

–
Pain2 of 3 · compare here–

Menarini Group in Pain: 1 program

  1. Ibuprofenphase 1

Their studies: Menarini Group’s studies of Pain in search

Haisco Pharmaceutical Group in Pain: 1 program

  1. HSK55718phase 2

Their studies: Haisco Pharmaceutical Group’s studies of Pain in search

Pain, Postoperative2 of 3 · compare here–

Menarini Group in Pain, Postoperative: 1 program

  1. Ibuprofenphase 1

Their studies: Menarini Group’s studies of Pain, Postoperative in search

Haisco Pharmaceutical Group in Pain, Postoperative: 1 program

  1. anrikefonphase 3

Their studies: Haisco Pharmaceutical Group’s studies of Pain, Postoperative in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

Gilead Sciences in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. domvanalimabphase 3

Their studies: Gilead Sciences’ studies of Squamous Cell Carcinoma of Head and Neck in search

–

Haisco Pharmaceutical Group in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Squamous Cell Carcinoma of Head and Neck in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Gilead Sciences 16 of 32 · Menarini Group 6 of 7 · Haisco Pharmaceutical Group 7 of 27 programs (23 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.